IBC
IBC Overview eLearning Module
Institutional biosafety committee oversight is necessary to ensure the safety of those involved in research with engineered genetic materials.
Daniel Eisenman, Paul Gulig, and Adam Soloff Explore The Exponential Rise of Gene Therapy and Unlocking Its Potential Promise
In this podcast, Daniel Eisenmann talks with Adam Soloff and Paul Gulig for a discussion on the growth and the promise of gene therapy.
Improving Access to Research for Diverse and Underserved Populations
Increasing diversity and inclusion in research has long been a challenge in the clinical research community. Learn strategies to increase access to clinical trials for all.
Industry-Wide Solutions to Improve Access to Clinical Trials
In this discussion, panelists provide actionable strategies for improving access to clinical research for diverse, underserved populations.
World’s Largest CRO Leverages Partnership With Integrated Central IBC to Initiate Sites in COVID-19 Vaccine Research at Warp Speed
Advarra’s IRB and IBC reviews and Gene Therapy Ready site network helped reduce study startup timelines and delivered trial results to the sponsor quicker than expected.
What Is an Institutional Biosafety Committee?
An institutional biosafety committee (IBC) ensures research is conducted safely and in compliance with the NIH guidelines. Watch our video to learn the role of an IBC.
Q&A: FDA Inspections of Clinical Investigators: Understanding the Process and What to Expect
Q&A from our 4/21 webinar outlining what to expect in an FDA inspection and how to have a more positive experience.
Study Startup Success for BioPharma and MedTech: Engage a Research Compliance Partner
Engaging with an expert research compliance partner throughout the clinical development process allows researchers to focus on what matters
Cheryl Byers and Dr. John H. Stewart Discuss Diversity, Equity and Inclusion in Cancer Research
Diversity, equity, and inclusion (DEI) in cancer research are critical to clinical research. In this episode, Advarra’s Cheryl Byers and Dr. John H. Stewart have a discussion on what is DEI, the current climate of DEI in cancer research, and considerations to improve DEI in clinical trial enrollment and retention.
The State of Clinical Trial Activation at Sites Report
View our report on actions to streamline study activaiton and maximize operational efficiency.
Meridian Builds Robust Gene Therapy Research Program
Partnering with Advarra’s Institutional Biosafety Committee, Meridian Clinical Research established a program for conducting clinical trials with cutting edge, genetically engineered vaccines.
How Sites Can Win in the New Age of Genetically Engineered Treatments
The accelerating gene therapy market is expected to grow 16.6 percent by 2027. As gene therapies enter the pipeline, how can sites prepare themselves to take advantage of the rush?
Subscribe to our monthly email
Receive updates monthly about webinars for CEUs, white papers, podcasts, and more.
Advancing Clinical Research: Safer, Smarter, Faster™
Copyright © 2024 Advarra. All Rights Reserved.